HRTX Heron Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

HRTX [NASD]

Heron Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.27	Insider Own	0.13%	Shs Outstand	90.41M	Perf Week	9.26%
Market Cap	1.48B	Forward P/E	-	EPS next Y	-1.56	Insider Trans	-0.98%	Shs Float	84.49M	Perf Month	-12.53%
Income	-193.30M	PEG	-	EPS next Q	-0.64	Inst Own	-	Short Float	22.24%	Perf Quarter	10.44%
Sales	139.80M	P/S	10.56	EPS this Y	-2.50%	Inst Trans	0.33%	Short Ratio	13.16	Perf Half Y	-26.16%
Book/sh	4.04	P/B	4.06	EPS next Y	40.50%	ROA	-43.00%	Target Price	-	Perf Year	-10.33%
Cash/sh	3.96	P/C	4.14	EPS next 5Y	47.50%	ROE	-56.90%	52W Range	9.60 - 26.81	Perf YTD	-30.21%
Dividend	-	P/FCF	-	EPS past 5Y	2.70%	ROI	-51.50%	52W High	-38.83%	Beta	1.69
Dividend %	-	Quick Ratio	4.20	Sales past 5Y	-	Gross Margin	60.20%	52W Low	70.83%	ATR	1.20
Employees	231	Current Ratio	4.50	Sales Q/Q	-19.60%	Oper. Margin	-	RSI (14)	47.88	Volatility	4.98% 6.58%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	29.00%	Profit Margin	-	Rel Volume	1.50	Prev Close	15.64
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	1.43M	Price	16.40
Recom	1.60	SMA20	-7.62%	SMA50	-5.10%	SMA200	-13.62%	Volume	2,135,602	Change	4.86%

May-27-20

Initiated

Guggenheim

Buy

$24

Feb-20-20

Reiterated

Needham

Buy

$50 → $48

Jan-16-19

Reiterated

Needham

Buy

$66 → $64

Apr-05-18

Initiated

Evercore ISI

Outperform

$56

Mar-19-18

Reiterated

Mizuho

Buy

$28 → $35

Mar-01-18

Reiterated

Needham

Buy

$28 → $30

Jan-03-18

Initiated

Leerink Partners

Outperform

$22

Sep-27-17

Initiated

Northland Capital

Outperform

$40

Feb-27-17

Initiated

Needham

Buy

$28

Oct-26-16

Initiated

Aegis Capital

Buy

Sep-06-16

Resumed

Lake Street

Buy

$45

May-03-16

Initiated

Cantor Fitzgerald

Buy

Dec-10-15

Initiated

Lake Street

Buy

$45

Sep-23-15

Reiterated

Leerink Partners

Outperform

$38 → $57

Sep-02-15

Initiated

BofA/Merrill

Buy

$46

Aug-03-15

Reiterated

Brean Capital

Buy

$40 → $45

Jun-30-15

Reiterated

JMP Securities

Mkt Outperform

$25 → $33

Jun-19-15

Reiterated

Leerink Partners

Outperform

$26 → $38

Aug-07-14

Initiated

Noble Financial

Buy

$18

Jul-02-20 10:38PM	Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher Zacks
Jul-01-20 02:26PM	Heron Therapeutics: HTX-011 Will Eventually Be Approved, Says Analyst SmarterAnalyst +9.04%
Jun-30-20 11:15AM	Heron's Pain Management Drug Gets Complete Response Letter Zacks
Jun-29-20 08:47AM	Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options Zacks -28.08%
08:45AM	Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain PR Newswire
Jun-26-20 08:28AM	The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts Benzinga
Jun-23-20 07:51PM	Here is What Hedge Funds Think About Heron Therapeutics Inc (HRTX) Insider Monkey
Jun-21-20 02:53PM	The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Benzinga
Jun-16-20 10:00AM	2 Top Healthcare Stocks to Watch in June Motley Fool
Jun-04-20 09:00AM	Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty PR Newswire
May-20-20 10:04AM	Billionaire Jim Simons Pulls the Trigger on These 3 Healthcare Stocks TipRanks
May-18-20 09:00AM	Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain PR Newswire +7.01%
May-09-20 08:00AM	3 Best Healthcare Stocks to Buy in May Motley Fool
May-08-20 10:04AM	Earnings Update: Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported And Analysts Are Trimming Their Forecasts Simply Wall St.
May-06-20 10:35AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates Zacks
09:00AM	Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2020 and Highlights Recent Corporate Updates PR Newswire
May-05-20 07:31AM	Does Heron Therapeutics, Inc. (NASDAQ:HRTX) Have A Particularly Volatile Share Price? Simply Wall St.
Apr-19-20 07:02AM	3 Top Biotech Stocks with FDA Approvals on the Horizon TipRanks
Apr-09-20 04:05PM	Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference PR Newswire
Apr-07-20 03:33PM	Do Hedge Funds Love Heron Therapeutics Inc (HRTX)? Insider Monkey +6.03%
Apr-05-20 09:57AM	Despite Lacking Profits Heron Therapeutics (NASDAQ:HRTX) Seems To Be On Top Of Its Debt Simply Wall St.
Mar-02-20 09:05AM	Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:30AM	Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates PR Newswire
Feb-27-20 01:19PM	Analysts: 3 Beaten-Down Stocks to Buy on Weakness TipRanks
08:42AM	The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals Zacks
Feb-26-20 04:42PM	Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio Zacks
Feb-21-20 12:30PM	Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
Feb-20-20 07:06AM	The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Benzinga
Feb-19-20 06:16PM	3 Strong Buy Healthcare Stocks With Fast-Approaching Catalysts TipRanks
Feb-18-20 04:05PM	Heron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference PR Newswire
Jan-27-20 11:01AM	Introducing Heron Therapeutics (NASDAQ:HRTX), The Stock That Zoomed 186% In The Last Five Years Simply Wall St.
Jan-22-20 08:53AM	Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8% Zacks +6.61%
Jan-13-20 08:30AM	Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises PR Newswire +5.66%
Dec-21-19 08:27AM	When Will Heron Therapeutics, Inc. (NASDAQ:HRTX) Turn A Profit? Simply Wall St.
Dec-16-19 04:05PM	Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain PR Newswire
Dec-12-19 01:44PM	Hedge Funds Cashed Out Of Heron Therapeutics Inc (HRTX) Too Early Insider Monkey
Dec-10-19 05:18AM	Moving Average Crossover Alert: Heron Therapeutics Zacks
Dec-06-19 08:00AM	12 Biotech Stocks Primed For A Short Squeeze Benzinga
Dec-03-19 07:30AM	Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain PR Newswire
Nov-26-19 04:05PM	Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference PR Newswire
Nov-25-19 09:13AM	Heron Therapeutics, Inc. (HRTX) Shares March Higher, Can It Continue? Zacks
Nov-22-19 03:22PM	3 Strong Buy Biotech Stocks to Watch After Stifel Healthcare Conference TipRanks
Nov-15-19 09:00AM	Heron Therapeutics (HRTX) Upgraded to Buy: Here's Why Zacks
08:24AM	Heron Therapeutics, Inc. Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St.
Nov-14-19 04:05PM	Heron Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire
Nov-13-19 04:05PM	Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference PR Newswire
Nov-12-19 09:45AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates Zacks
08:30AM	Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates PR Newswire
Nov-11-19 01:59PM	Is Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Pay Fair? Simply Wall St.
Oct-30-19 10:33AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
05:15AM	2 Small Biotech Stocks Spurt Ahead on Positive Developments TheStreet.com
Oct-28-19 09:08AM	Is Heron Therapeutics Inc (HRTX) Going to Burn These Hedge Funds? Insider Monkey +5.86%
08:30AM	Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain PR Newswire
Oct-22-19 08:30AM	Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC) PR Newswire
Oct-07-19 12:14PM	Weekly CEO Buys Highlight GuruFocus.com
Oct-04-19 10:00PM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm GlobeNewswire -10.04%
06:10AM	How Heron Therapeutics, Inc. (NASDAQ:HRTX) Can Impact Your Portfolio Volatility Simply Wall St.
Oct-03-19 10:37PM	Heron Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire
04:01PM	Heron Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
09:42AM	Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2% Zacks
Oct-02-19 12:23PM	Heron Shares Rise on Phase III Results of Agent Used in Knee Replacements TheStreet.com +6.15%
07:45AM	Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty PR Newswire
Oct-01-19 04:10PM	Heron Therapeutics Appoints Kimberly Manhard to Board of Directors PR Newswire -5.08%
04:05PM	Heron Therapeutics Appoints Stephen Davis to Board of Directors PR Newswire
08:30AM	Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain PR Newswire
Sep-25-19 04:05PM	Heron Therapeutics to Present at the 2019 Cantor Global Healthcare Conference PR Newswire
Sep-04-19 10:00AM	How Many Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Aug-30-19 06:14PM	5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Aug-29-19 07:31AM	The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You? Motley Fool +6.47%
Aug-20-19 08:30AM	Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery PR Newswire
Aug-06-19 03:40PM	Biotech Stocks to Watch Through the 2nd Half of 2019 GuruFocus.com
Aug-05-19 03:30PM	FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of HRTX, EGBN and CARB ACCESSWIRE
03:00PM	Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 PR Newswire
02:18PM	Is Heron Therapeutics (NASDAQ:HRTX) Using Debt Sensibly? Simply Wall St.
10:45AM	SHAREHOLDER ALERT: HRTX RBGLY JE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
10:30AM	Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 ACCESSWIRE
09:45AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:30AM	Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Updates PR Newswire
08:15AM	MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Aug-02-19 03:30PM	CLASS ACTION UPDATE for HRTX, EROS and MNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
03:00PM	Final Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 GlobeNewswire
09:43AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, STG, PVTL and GTT GlobeNewswire
07:10AM	Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. HRTX GlobeNewswire
Aug-01-19 04:00PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HRTX, RLGY and NFLX ACCESSWIRE
02:46PM	LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm GlobeNewswire
Jul-31-19 02:00PM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, PVTL and INS ACCESSWIRE
12:53PM	SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline HRTX GlobeNewswire
11:15AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, PVTL and RBGLY ACCESSWIRE
10:29AM	Approaching Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 ACCESSWIRE
Jul-30-19 07:05PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HRTX, NFLX and LB ACCESSWIRE
06:30PM	Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Beazer Homes, and Cloudera and Encourages Investors to Contact the Firm GlobeNewswire
11:20AM	CLASS ACTION UPDATE for MMM, HRTX, CTST and NGHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:47AM	HRTX CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors That Approximately 6 Days Remain To Make A Motion For Lead Plaintiff In A Securities Class Action Lawsuit Against Heron Therapeutics, INC. HRTX GlobeNewswire
Jul-29-19 03:00PM	3 Top Biotech Stocks to Buy Right Now Motley Fool
02:15PM	CLASS ACTION UPDATE for HRTX, STG and RLGY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
01:32PM	ROSEN, A TOP RANKED LAW FIRM, Reminds Heron Therapeutics, Inc. Investors of Important August 5th Deadline in the Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm HRTX GlobeNewswire
10:45AM	CLASS ACTION UPDATE for CYH, HRTX and EROS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
10:28AM	Upcoming Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 ACCESSWIRE
09:10AM	7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jul-26-19 04:15PM	SHAREHOLDER ALERT: HRTX EQT FRED: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MANHARD KIMBERLY	Executive VP, Drug Development	May 01	Sale	13.97	1,158	16,176	0	May 01 06:48 PM
MANHARD KIMBERLY	Executive VP, Drug Development	Nov 29	Option Exercise	13.00	24,000	312,000	24,000	Dec 03 06:30 PM
MANHARD KIMBERLY	Executive VP, Drug Development	Nov 29	Sale	26.00	24,000	624,000	0	Dec 03 06:30 PM
TANG KEVIN C	Director	Oct 04	Buy	17.50	285,714	4,999,995	5,799,810	Oct 07 05:18 PM
Quart Barry D	Chief Executive Officer	Oct 03	Buy	17.50	4,571	79,993	94,652	Oct 04 07:58 PM
POYHONEN JOHN	EVP, Chief Commercial Officer	Oct 03	Buy	17.50	5,143	90,003	18,143	Oct 04 07:56 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience